WAT

Business profile & competitive position

Waters Corporation (WAT) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. Its main business is designing, manufacturing, selling and servicing analytical instruments—high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA)—plus the consumables, software and service plans that support those systems. After the February 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses, Waters also offers diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools. In 2025, 59% of net sales went to pharmaceutical accounts, 30% to other industrial accounts and 11% to academic and government agencies, with no single customer accounting for more than 2% of net sales.

Service revenue represented more than 35% of Waters’ 2025 sales and more than 25% of TA’s 2025 sales, giving the business a recurring-revenue component alongside instrument sales. The financial profile, though, does not point to an obviously wide competitive moat on a pure profitability basis: net margin is 3.6% and ROE is 1.9%. Both are low relative to what a mature analytical-instrument franchise might generate, suggesting the company is absorbing acquisition-related costs or operating in a product cycle that requires continued R&D and manufacturing scale before margins expand. The sticky service attach and customer diversification are supportive, but by themselves they are not enough to infer durable pricing power.

Financial posture

Waters currently has a market capitalization of $31.8 billion and trades at a P/E ratio of 105.7. Those headline figures sit alongside a net margin of 3.6%, an ROE of 1.9% and a beta of 1.19. The stock is at $424.82, with a 50-day EMA of $400.40 and an RSI of 60.8, meaning it is trading above its recent moving average and near neutral-to-slightly-elevated momentum territory.

The valuation multiple is unusually high relative to current earnings power. A P/E above 100, paired with a net margin below 4% and ROE below 2%, implies the market is pricing in meaningful improvement from the BD Biosciences and Diagnostic Solutions acquisition, new product cycles and eventual margin recovery rather than pricing the recent earnings run rate. Beta of 1.19 indicates the stock has modestly higher volatility than the broad market, which fits a post-deal integration story in capital equipment. The balance sheet is also materially shaped by the acquisition: the BDS Business Acquisition closed on February 9, 2026 for $16.8 billion including assumed debt, so leverage and goodwill will be central to the financial story in coming quarters.

Strategic priorities & outlook

In its most recent 10-K, Waters laid out a post-acquisition playbook centered on reorganizing the combined company into four operating segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. Management said it will evaluate the newly organized business activities to determine operating and reporting segments for future filings. R&D spending is expected to remain substantial, focused on developing new products and enhancing existing LC, MS, TA and diagnostics offerings.

The company also said it intends to pursue additional outsourcing opportunities while maintaining adequate internal supply chain and manufacturing capabilities. Structurally, the BDS Business Acquisition was a $16.8 billion transaction including assumed debt, executed as a Reverse Morris Trust, with BD shareholders owning approximately 39.2% of the combined company. That ownership structure leaves a large block of legacy BD shareholders tied to Waters’ execution, and future segment disclosures will be closely watched for how profitable each division is on a standalone basis.

Macro & geopolitical exposure

As a Medical - Diagnostics & Research company, Waters is exposed to several macro and policy channels. Its largest end market, pharmaceutical R&D, is tied to global biopharma capital spending and drug-development pipelines. Any pullback in large-cap pharma budgets or in venture-stage life-sciences funding can slow instrument purchases and consumables pull-through. Academic and government customers accounted for 11% of 2025 sales, so grants, public-health budgets and science-agency funding have a direct read-through.

The diagnostics business adds regulatory exposure. FDA clearances, laboratory-developed-test rules and reimbursement decisions from payors influence how quickly new tests and specimen-collection products can scale. Because the company sources and sells instruments and consumables globally, it is also sensitive to currency translation, tariffs and trade-policy shifts that affect capital equipment and life-science supply chains. Outsourced manufacturing, as referenced in company disclosures, adds a supply-chain dimension: disruptions in components or logistics could affect delivery timelines for LC, MS, TA and diagnostics platforms.

Recent developments

The news flow since mid-September 2026 has focused on flow cytometry and at-home diagnostics, signaling how Waters is commercializing the BD Biosciences assets. On September 18, 2026, Zacks reported that Waters launched the BD FACSDiscover A7 for advanced flow cytometry. On September 16, 2026, BusinessWire announced a partnership between Everlywell and Waters Corporation to bring what the companies described as the most comprehensive FDA-cleared at-home HPV cervical cancer screening tool available in the U.S. to patients. On September 14, 2026, PRNewswire covered the commercial launch of the BD FACSDiscover A7 Cell Analyzer, which Waters said sets a benchmark for standardized spectral flow cytometry. Earlier, on September 11, 2026, Waters announced it would present at the J.P. Morgan U.S. All Stars Conference.

Together, these headlines point to a strategic emphasis on expanding diagnostics reach—especially cancer screening—alongside the core analytical-sciences franchise. The partnership approach for consumer diagnostics may become a recurring theme as Waters converts its regulatory capabilities into broader clinical access.

Earnings behavior & post-earnings drift

Waters’ earnings track record over the past eight reported quarters is spotless: it has beaten estimates in all eight quarters, for a 100% beat rate, with an average earnings surprise of 4.7%. The average five-day price move after those reports has been +2.67%, classified as an upward post-earnings drift.

The most recent four quarters show the trend in action, but also highlight that post-earnings price action is not uniformly positive. On August 4, 2026, the company reported EPS of $3.05 versus an estimate of $3.01, a 1.3% surprise; the stock rose 0.99% the next day and 4.78% over the following five days. On May 5, 2026, EPS came in at $2.70 against $2.31 estimated, a 16.9% beat; the stock rose 2.04% the next day and 2.83% over five days. On February 9, 2026, EPS of $4.53 barely beat the $4.51 estimate, a 0.4% surprise; the stock slipped 0.34% the next day and 2.04% over the following five days, the exception in this window. On November 4, 2025, EPS of $3.40 beat the $3.21 estimate by 5.9%, and the stock climbed 1.26% the next day and 5.12% over five days.

Looking ahead, Waters is scheduled to report on November 3, 2026 before the market open, with a consensus EPS estimate of $4.01. The 100% beat streak and positive average drift inform how the market’s real expectation may be set, but they do not guarantee a particular outcome; the February 2026 quarter shows that even a slight beat can be followed by a negative five-day drift when the unofficial consensus had already priced in more.

For investors weighing the $31.8 billion valuation, the 105.7 P/E, the $16.8 billion BDS integration and the 100% earnings-beat streak, the next step is to cross-reference these figures against full sell-side estimates, management commentary and margin-trajectory assumptions in the complete institutional research consensus.